about
Panobinostat for the treatment of multiple myeloma: the evidence to dateCeritinib: A primer for pharmacists.Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancerSurvival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma.Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma.Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung CancerBRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2.The pharmacoeconomics of breakthrough cancer pain.Diagnosis and treatment of cancer-related anemia.Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database.Treatment Patterns and Outcomes in Patients With Hepatocellular Carcinoma Stratified by Stage-Guided Treatment Categories.Effect of treatment dose reductions in the setting of hand-foot syndrome on survival outcomes in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor receptor inhibitors.Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone.Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2.Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies.Adherence to Oral Medications During Maintenance Therapy Among Children and Adolescents With Acute Lymphoblastic Leukemia: A Medication Refill Analysis.A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis.Correlation of degree of hypothyroidism with survival outcomes in patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.Aspirin and Cancer Risk.Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma.Impact of a genetic counseling requirement prior to genetic testing.PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancerPhase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancerPredictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinomaCharacterization and survival of patients with metastatic basal cell carcinoma in the Department of Veterans Affairs: a retrospective electronic health record reviewDynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reportsComparative efficacy and safety of interventions for preventing chemotherapy-induced oral mucositis in adult cancer patients: a systematic review and network meta-analysisImmunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer centerClinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer CenterEvolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and timeTime from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer
P50
Q26778674-929914F7-F2F4-4C78-B311-167A3CC49D25Q30244613-40E1844C-6496-40C5-8D0E-C853DFA9A038Q34446385-DAF97A1B-4694-4092-BD08-E26AEE4DEDECQ35061439-B5DD195C-B8DC-4B38-B172-657826B440BFQ36241273-9E59C6ED-2F04-48CF-AD3C-85789F56F86FQ36558386-FA1A5EE9-5330-4349-B044-150F0E38CC6AQ36714988-CD3D4041-C500-4AB5-A0C3-4FE445F2E264Q37301538-16ED9CA1-CC4A-4748-8F53-4B5CB08EC688Q38108027-8751295F-7CDB-4C21-86CA-8FDEF062AAA6Q38188501-4A871D4A-B2F8-4DE2-BFFE-308F77DEAB0AQ38237525-7D8F32B5-A9A5-4A1C-80E2-3DF2E53C2C86Q38569038-26A483DD-828A-46F4-8BC0-A05CA7A325C2Q38823652-F0BC637D-293C-4C0A-8A9F-FB6E6D77C2C3Q38993677-56AEDE4B-59E3-4844-A64F-72F77FDC1841Q39699164-BF20A29B-401D-4B71-8E93-D5654E18C593Q42690907-CF95E031-5BB0-4CB7-A73D-B240AE4469E4Q44383576-60BFDF31-B297-4FD6-9F27-6F7FFA6A818FQ47635554-D5F033B4-DDD3-4E45-A768-A0B07FB42579Q49499792-F127BD4B-A164-4237-86BE-ACE279FBEBAAQ51780331-055B28B9-826B-4DCF-8D05-1B8C3DCB8162Q53671577-022482D1-2E16-431A-83BE-D00BD8C0C829Q53758033-4621001B-D5A8-4338-8A49-0973E1A712B4Q54977352-8CBB60E1-3E2F-4F15-AA3C-9E85C8FD753AQ55058019-7EC1CB43-4655-4329-A1AC-58416396C425Q57073426-322216A2-7E23-4C09-BF4E-2E60593797A5Q57284279-04FCCE24-A0E4-4341-B57C-14C07E5BB1BEQ61809891-50F1D955-B796-4D1E-A3A8-933A20DED177Q88601054-4D53C20E-B18C-4745-A8F8-B1CDF719E40AQ89937360-E6E49856-B7EA-4F50-BABC-ABB82518A795Q90055798-16481DA7-3F83-4A16-9B48-985304D7BCBFQ91248210-C2FEF62B-FFF7-48AA-AAA2-9F8CB4D4EE8CQ91398105-DED540DB-A0EF-4D52-8228-FE78E3DE1E5DQ91456703-E023AD40-E702-442C-A861-F515D408F82EQ91632056-274B2370-561B-44F1-91BA-11A7F4EB1F81
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
David D Stenehjem
@en
David D Stenehjem
@nl
type
label
David D Stenehjem
@en
David D Stenehjem
@nl
prefLabel
David D Stenehjem
@en
David D Stenehjem
@nl
P31
P496
0000-0002-1831-285X